InvestorsHub Logo
Followers 594
Posts 20577
Boards Moderated 0
Alias Born 02/01/2012

Re: jour_trader post# 239315

Tuesday, 01/17/2017 10:32:37 AM

Tuesday, January 17, 2017 10:32:37 AM

Post# of 402088
$ELTP is the expert at Commercial pricing of their ANDAs and exactly why their ANDAs are growing increased revenues now at +$12 mil/yr.

While the Courts ruled in favor of TEVA's Oxycontin Generic in Feb 2016 it is not certain what Purdue is planning to do next, if anything.


http://www.reuters.com/article/us-oxycontin-ruling-idUSKCN0VA3GC

HEALTH NEWS | Mon Feb 1, 2016 | 8:18pm EST
U.S. appeals court ruling may clear barrier to generic OxyContin



TEVA has been currently selling their authorized NDA Generic ER Oxycontin since the Higher Court ruling.

A federal appeals court ruled Monday that four patents related to Purdue Pharma's painkiller OxyContin are invalid




https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d574a71a-2fe0-4cb7-95be-0a3c32e4e92e

It is looking more like Purdue has accepted legal defeat and exactly why $ELTP is now ready to submit its own Oxycontin ADF ANDA!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News